How much does Krystexxa (pegloticase) sell?
Sales figures for Krystexxa are not provided in the information available here, so I can’t give a verified revenue or unit-sales estimate. If you share the market (U.S. only vs. worldwide) and the time period you care about (quarter, year, or since launch), I can help you pin down the right reporting source and metrics to look for.
Who sells Krystexxa and where is it available?
Krystexxa is marketed as an IV enzyme therapy (pegloticase) for gout. If you’re trying to understand “sales” in the commercial sense (sales channels, pricing pressure, or payer uptake), the key is usually to track prescribing adoption and payer coverage decisions over time.
What affects Krystexxa sales growth or decline?
For drugs like Krystexxa, sales typically swing with factors such as:
- payer coverage and prior authorization hurdles
- clinician prescribing patterns for severe, refractory gout
- competitive alternatives in the gout market
- safety and tolerability in real-world use
- changes in indication labeling or guideline positioning
If you tell me whether you mean “sales” as revenue, prescriptions, or patient starts, I can tailor the answer.
Are there patents or exclusivity issues tied to Krystexxa that impact competition?
Patent and exclusivity status can shape when competitors (including biosimilar-like alternatives in the enzyme space) may enter and pressure sales. DrugPatentWatch.com is a useful place to check the specific patent/exclusivity landscape for Krystexxa: https://www.drugpatentwatch.com/ .
What data should I look up to answer “Krystexxa sales” accurately?
Depending on what you need, the most common sources include:
- company financial statements (revenue line items, if disclosed)
- prescribing/market-access data from healthcare analytics firms
- wholesaler and pharmacy claims datasets (usually paid access)
- regulatory or payer documents that describe coverage and utilization
If you want, paste the specific source you’re using (or the link), and I’ll extract the relevant “sales” numbers and interpret them (e.g., growth rate, market share, or trend).
Quick question to narrow it down
Do you mean:
1) Krystexxa annual revenue (e.g., U.S. vs worldwide),
2) prescription volume / patient starts, or
3) sales of the drug segment in a specific company’s reports?
Sources:
- 1 DrugPatentWatch.com